Vice President of Sales Justyn Okoniewski will seek to increase market
share for IHS's highly accurate syringe infusion system.
CHESTER,
N.Y., Aug. 5, 2024 /PRNewswire/ -- Innovative
Health Sciences ("IHS" or the "Company"), a medical device company
that creates state-of-the-art drug infusion solutions, announced
today the expansion of its commercialization team to market the
Insignis™ Syringe Infusion System. The System was cleared by FDA on
March 1, 2024, and features a 13.5psi
mechanical syringe driver and a highly accurate selectable rate
flow control device (for intravenous and subcutaneous use), which
brings affordable, effective, convenient infusion for patients in a
variety of settings, including ambulatory, hospital, clinic, and
home. As Vice President of Sales, Justyn
Okoniewski will accelerate business growth and
commercialization.
![IHS logo IHS logo](https://mma.prnewswire.com/media/2475495/IHS_Logo.jpg)
Insignis is the first combination of an intravenous and
subcutaneous non-electric infusion pump created for use with a
highly accurate selectable rate flow control
device. The Insignis™ system brings a fresh, novel approach to the
forefront of the infusion industry defined by convenience, safety,
innovation, and autonomy as for SCIg patients are now empowered to
select, titrate, and modify the flow rate in real-time. This
revolutionary improvement in infusion technology is dramatically
altering the infusion therapy experience by finally finding a
solution to painful site reactions. With Insignis, patients can
mitigate, reduce, and even prevent the occurrence of common site
reactions.
Justyn brings over ten years of infusion expertise to the team
both in the intravenous and subcutaneous markets. He has worked
closely and extensively with providers, suppliers, and distributors
and will leverage his knowledge and contact base to contribute to
IHS' sales strategy.
"With the FDA clearance for our unique approach to delivering
medications, including the novel tapered flow technique, we're on
the cusp of shifting the paradigm in our field, making critical
infusions more comfortable, affordable, and accessible than ever,"
said Andrew Sealfon, Founder and
Chairman at Innovative Health Sciences. "I'm excited to welcome
Justyn to the team where he will help lead IHS into the next phase
of development and growth."
"I'm thrilled to join Innovative Health Sciences team at this
exciting time. IHS is at the forefront of revolutionizing infusion
technology. Our solutions offer a unique combination of
portability, cost-effectiveness, and precision that have the
potential to significantly improve patient care and quality of
life," said Justyn Okoniewski, Vice
President of Sales at IHS. "I'm eager to lead our sales efforts in
bringing these innovative solutions to healthcare providers and
patients worldwide, and making a meaningful difference in infusion
therapy."
The recently cleared infusion system consists of a syringe
based, non-electric portable 13.5psi constant pressure syringe
driver with carrying case and a state-of-the-art intravenous or
subcutaneous selectable rate flow control device. For the
intravenous administration of medication(s), the Insignis™
Intravenous (IV) Controller includes a selectable rate flow dial
and tubing for direct connection to an IV catheter. For the
administration of 20% subcutaneous immunoglobulin (SCIg) solutions,
the OneSett™ Subcutaneous Administration Set includes a selectable
rate flow controller, connected directly to an administration set
comprised of one (1) to up to four (4) 26 gauge needle set
configurations that meet the drug manufacturer's maximum flow rate
limits in all configurations. This smaller needle means less pain
while still maintaining maximum flow rate performance. The flow
rate directly indicated on the dial is delivered to each needle
site – no calculation required! IHS also offers generic, newly
improved 26-gauge subcutaneous needle sets as well as the
Q-Controller™ Subcutaneous Administration Set (currently only
available in EU) for the infusion of 10% IgG medications such as
Hyqvia® for up to 300ml/hr to each site. For additional information
on the FDA clearance, please visit this website:
https://www.accessdata.fda.gov/cdrh_docs/pdf23/K232328.pdf
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC
provides breakthrough solutions to the infusion healthcare market.
IHS' approach is patient-centric and future-oriented; our goal is
to provide the highest quality of life by empowering the patient to
take control of their infusion. IHS is successfully taking the
confusion out of the infusion for all parties in the industry:
clinicians, pharmacists, and most importantly, patients. The
Insignis™ System is FDA cleared for marketing in USA, CE Mark
approved, and MDSAP and ISO 13485 certified.
For more information on the Company and the products, be sure to
click the link below: https://www.innohealthsci.com/
Forward-Looking Statements
The statements contained
herein are not guaranteed of future performance and undue reliance
should not be placed on them. Such Forward-Looking Statements
necessarily involve known and unknown risks and uncertainties,
which may cause actual performance and financial results in future
periods to differ materially from any projections of future
performance or results expressed or implied. These statements are
based on management's beliefs and theory. The Company undertakes no
obligation to update Forward-Looking Statements if circumstances or
management's estimates or opinions should change, except as
required by applicable securities laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/innovative-health-sciences-expands-commercialization-team-to-market-insignis-syringe-infusion-system-after-receiving-fda-clearance-302214477.html
SOURCE Innovative Health Sciences LLC